Evoke Pharma (EVOK) Stock Statistics & Valuation Metrics

Evoke Pharma has a market cap or net worth of $6.55M. The enterprise value is -$4.82M.

Evoke Pharma has 1,492,858 shares outstanding. The number of shares has decreased by -2.65% in one year.

Evoke Pharma’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -42.66%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Evoke Pharma had revenue of 10.25M and earned -5.35M in profits. Earnings per share was -2.81.

In the last 12 months, operating cash flow was -3.88M and capital expenditures 0.00, giving a free cash flow of -3.88M billion.

Evoke Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Evoke Pharma upcoming earnings date is Aug 7, 2025, TBA (Confirmed).

Evoke Pharma as a current ratio of 1.66, with Debt / Equity ratio of 2.48%

In the past 12 months, Evoke Pharma has paid 0.00 in taxes.

Evoke Pharma EV to EBITDA ratio is <0.01, with an EV/FCF ratio of <0.01.

Evoke Pharma has $12.62M in cash and marketable securities with $144.84K in debt, giving a net cash position of -$12.48M billion.

Gross margin is 97.36%, with operating margin of -50.77%, and net profit margin of -52.22%.

The average price target for Evoke Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―